Pavay Biological Technology

Pavay Biological Technology is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, specializing in the development of innovative small molecule drugs for oncology. The company focuses on targeting the RAS signaling pathway, with a lead program centered on SOS1 inhibitors for the treatment of KRAS-mutant solid tumors. Pavay utilizes a structure-based drug design approach to create highly selective and potent therapeutic candidates. Its mission is to address significant unmet medical needs in cancer treatment through precision medicine. The company's pipeline also includes programs targeting other key nodes in oncogenic signaling pathways, such as SHP2. Pavay is supported by prominent venture capital firms and aims to advance its candidates through global clinical development.